Name: Latest research reports of Gland Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Gland Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Gland Pharma Ltd.

NSE: GLAND | BSE: 543245 | ISIN: INE068V01023 | Industry: Pharmaceuticals
| Mid-range Performer

1724.1000 13.60 (0.80%)

NSE Mar 27, 2026 15:31 PM

34.93% Gain from 52W Low

Volume: 90,957

Gland Pharma Ltd.

28 Jan 2026, 12:00AM

1724.10

0.80%

Cenexi break-even/US uptrend drives earnings beat

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered better-than-expected 3QFY26 financial performance with a 6%/14%/19% beat on revenue/EBITDA/PAT.

Gland Pharma Ltd. has an average target of 2165.00 from 3 brokers.